Sector News

Gilead secures access to NASH drug in $1.2-bn deal

April 5, 2016
Life sciences

Gilead Sciences is snapping up a subsidiary of Nimbus Therapeutics for access to its experimental therapy for a metabolic disorder causing fat buildup in the liver.

The firm is prepared to shell out $1.2 billion under the deal; $400 million for Nimbus Apollo and a further $800 million to parent company Nimbus Therapeutics if certain developmental, regulatory and sales milestones are met.

The Nimbus Apollo programme includes lead candidate NDI-010976, an ACC inhibitor, and other preclinical ACC inhibitors for the treatment of non-alcoholic steatohepatitis (NASH), and for the potential treatment of hepatocellular carcinoma (HCC) and other diseases.

NDI-010976 was granted Fast Track designation by the US Food and Drug Administration in February; Phase I data for the compound are to be presented next month during at The International Liver Congress 2016, the annual meeting of the European Association for the Study of the Liver (EASL).

NASH is a serious liver disease resulting from metabolic dysfunction that causes toxic build-up of fat in the liver (steatosis) that can lead to inflammation, hepatocellular injury, progressive fibrosis and cirrhosis. The condition currently affects up to 15 million people in the US and, as Gilead notes, is expected to become the leading indication for liver transplantation by 2020.

“The acquisition of Nimbus’ ACC-inhibitor program represents a timely and important opportunity to accelerate Gilead’s ongoing efforts to address unmet needs in NASH,” said Norbert Bischofberger, Gilead’s chief scientific officer. “These molecules will complement and further strengthen Gilead’s pipeline and capabilities to advance a broad clinical program in NASH that includes compounds targeting multiple key pathways involved in the pathogenesis of the disease.”

By Selina McKee

Source: Pharma Times

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach